ROCKVILLE, Md., Aug. 8, 2013 /PRNewswire/ -- Synthetic
Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused
on the prevention and treatment of serious infectious diseases,
announced today that it intends to release its financial results
for the second quarter ended June 30,
2013 on Wednesday, August 14,
2013.
The Company will hold an investor conference call on
Wednesday, August 14, 2013, at
4:00 pm EDT. During the call,
Jeffrey Riley, Synthetic Biologics'
Chief Executive Officer, will provide a brief update of the
Company's multiple sclerosis program and its infectious disease
pipeline, including its oral enzyme candidate for the prevention of
C. difficile infections and monoclonal antibody candidates
for the treatment of Pertussis and Acinetobacter infections.
C. Evan Ballantyne, Synthetic
Biologics' Chief Financial Officer, will review the Company's
financial results for the second quarter ended June 30, 2013.
Interested parties should call 1-800-860-2442 (U.S. toll free),
1-866-605-3852 (Canada), or +1
412-858-4600 (International), fifteen minutes before the start of
the call to register. Registered callers on the toll free line may
ask to be placed in the queue for the Question & Answer
Session. The call will also be webcast over the Internet at
http://www.videonewswire.com/event.asp?id=95523. If you are unable
to participate during the live conference call, the webcast will be
available for replay at the same URL,
http://www.videonewswire.com/event.asp?id=95523 for 30 days after
the call.
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE MKT: SYN) is a biotechnology
company focused on the development of biologics for the prevention
and treatment of serious infectious diseases. The Company is
developing an oral enzyme for the prevention of C. difficile
infections, and a series of monoclonal antibody therapies for the
treatment of Pertussis and Acinetobacter infections. In
addition, the Company is developing a drug candidate for the
treatment of relapsing-remitting multiple sclerosis and cognitive
dysfunction in multiple sclerosis. For more information, please
visit Synthetic Biologics' website at
www.syntheticbiologics.com.
To download Synthetic Biologics' investor relations mobile
device app, which allows users access to the Company's SEC
documents, press releases and events, please click on the following
links to download the IRapp on your iPhone and iPad or your Android
mobile device.
SOURCE Synthetic Biologics, Inc.